Tissue-specific regulation of Fas/APO-1/CD95 expression by p53

被引:5
作者
Lin, PL [1 ]
Bush, JA [1 ]
Cheung, KJJ [1 ]
Li, G [1 ]
机构
[1] Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Div Dermatol, Dept Med, Vancouver, BC V6H 3Z6, Canada
关键词
Fas; p53; tumor suppressor; gene expression;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The regulation of Fas/APO-1(CD95), an important member of the tumor necrosis factor (TNF) superfamily involved in membrane-mediated apoptosis, has been a subject of recent research. Ligation of Fas by Fas ligand or an anti-Fas cross-linking antibody triggers receptor trimerization followed by recruitment of FADD to the cytoplasmic domain of the receptor and the activation of the caspase cascade. The tumor suppressor p53 has been shown to upregulate Fas expression under numerous pro-apoptotic stimuli in vitro. Using the p53 knockout mouse model, we demonstrate by Western, blot analysis, immunohistochemistry, and semi-quantitative RT-PCR that Fas expression is reduced in spleen and liver from p53(-/-) mice compared to p53(+/+) controls, while similar expression levels were observed in brain, heart, kidney, lung, skin, testis, and thymus between the two groups. While Fas protein was abundant in brain, heart, liver, and spleen, low levels of endogenous expression, was observed in other tissues from the p53(+/+) and p53(-/-) mice. These data indicate that p53 regulates Fas expression in a tissue-specific manner.
引用
收藏
页码:261 / 264
页数:4
相关论文
共 27 条
[11]   Mammalian caspases: Structure, activation, substrates, and functions during apoptosis [J].
Earnshaw, WC ;
Martins, LM ;
Kaufmann, SH .
ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :383-424
[12]   SPONTANEOUS AND CARCINOGEN-INDUCED TUMORIGENESIS IN P53-DEFICIENT MICE [J].
HARVEY, M ;
MCARTHUR, MJ ;
MONTGOMERY, CA ;
BUTEL, JS ;
BRADLEY, A ;
DONEHOWER, LA .
NATURE GENETICS, 1993, 5 (03) :225-229
[13]  
Hollstein M, 1997, Recent Results Cancer Res, V143, P369
[14]   Identification of two Fas-associated phosphatase-1 (FAP-1) promoters in human cancer cells [J].
Irie, S ;
Li, Y ;
Kanki, H ;
Ohyama, T ;
Deaven, LL ;
Somlo, S ;
Sato, TA .
DNA SEQUENCE, 2001, 11 (06) :519-526
[15]   TUMOR SPECTRUM ANALYSIS IN P53-MUTANT MICE [J].
JACKS, T ;
REMINGTON, L ;
WILLIAMS, BO ;
SCHMITT, EM ;
HALACHMI, S ;
BRONSON, RT ;
WEINBERG, RA .
CURRENT BIOLOGY, 1994, 4 (01) :1-7
[16]   Induction of apoptosis by cancer chemotherapy [J].
Kaufmann, SH ;
Earnshaw, WC .
EXPERIMENTAL CELL RESEARCH, 2000, 256 (01) :42-49
[17]   HEPATOCARCINOGENESIS IN P53-DEFICIENT MICE [J].
KEMP, CJ .
MOLECULAR CARCINOGENESIS, 1995, 12 (03) :132-136
[18]   p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs [J].
Müller, M ;
Wilder, S ;
Bannasch, D ;
Israeli, D ;
Lehlbach, K ;
Li-Weber, M ;
Friedman, SL ;
Galle, PR ;
Stremmel, W ;
Oren, M ;
Krammer, PH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (11) :2033-2045
[19]   Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis [J].
Munsch, D ;
Watanabe-Fukunaga, R ;
Bourdon, JC ;
Nagata, S ;
May, E ;
Yonish-Rouach, E ;
Reisdorf, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (06) :3867-3872
[20]   FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex [J].
Muzio, M ;
Chinnaiyan, AM ;
Kischkel, FC ;
ORourke, K ;
Shevchenko, A ;
Ni, J ;
Scaffidi, C ;
Bretz, JD ;
Zhang, M ;
Gentz, R ;
Mann, M ;
Krammer, PH ;
Peter, ME ;
Dixit, VM .
CELL, 1996, 85 (06) :817-827